Cargando…

Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution

BACKGROUND: Doxorubicin is the key drug for treatment of advanced soft tissue sarcoma (STS). The appropriate dosage of doxorubicin, regarding monotherapy or the role of combination therapy, is unclear. METHODS: We retrospectively reviewed patients with advanced or metastatic STS of nonextremities wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marshall, Shoko, Nakano, Kenji, Sugiura, Yoshiya, Taira, Shinichiro, Ono, Makiko, Tomomatsu, Junichi, Takahashi, Shunji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932429/ https://www.ncbi.nlm.nih.gov/pubmed/29849480 http://dx.doi.org/10.1155/2018/8926598

Ejemplares similares

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
por: Nakano, Kenji, et al.
Publicado: (2021)

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
por: Nakano, Kenji, et al.
Publicado: (2016)

Precision Medicine in Soft Tissue Sarcoma Treatment
por: Nakano, Kenji, et al.
Publicado: (2020)

Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma
por: Sato, Yasuyoshi, et al.
Publicado: (2021)

Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
por: Nakano, Kenji, et al.
Publicado: (2018)

An extragonadal germ cell tumor with dermatomyositis: A case report and literature review
por: Fujiwara, Yu, et al.
Publicado: (2020)

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
por: Yonemori, Kan, et al.
Publicado: (2018)

Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients
por: Fukuda, Naoki, et al.
Publicado: (2020)

Translocation-Related Sarcomas
por: Nakano, Kenji, et al.
Publicado: (2018)

Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial
por: Sato, Yasuyoshi, et al.
Publicado: (2020)

Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
por: Aoyama, Takeshi, et al.
Publicado: (2023)

Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
por: Ohmoto, Akihiro, et al.
Publicado: (2023)

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
por: Tian, Zhichao, et al.
Publicado: (2019)

Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy
por: Hayashi, Naomi, et al.
Publicado: (2021)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
por: Takahashi, Shunji, et al.
Publicado: (2021)

Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas
por: Liffers, Sven-T, et al.
Publicado: (2013)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter
por: Dang, Jing-Yi, et al.
Publicado: (2022)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma
por: Ohmoto, Akihiro, et al.
Publicado: (2021)

Neoadjuvant and adjuvant doxorubicin chemotherapy in a case of feline soft tissue sarcoma
por: Torrigiani, Filippo, et al.
Publicado: (2019)

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients
por: URAKAWA, HIROSHI, et al.
Publicado: (2014)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
por: Gong, Jun, et al.
Publicado: (2018)

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin
por: Kirilin, Evgeny M., et al.
Publicado: (2022)

Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study
por: Liu, Zhiyong, et al.
Publicado: (2021)

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
por: Takahashi, Shunji, et al.
Publicado: (2021)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
por: Nielsen, O. S., et al.
Publicado: (1998)

Alveolar soft part sarcoma metastatic to the breast: a case report
por: Asano, Yuka, et al.
Publicado: (2019)

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas: a systematic review and meta-analysis
por: Dang, Jingyi, et al.
Publicado: (2021)

Similar additive effects of doxorubicin in combination with photon or proton irradiation in soft tissue sarcoma models
por: Bernardo, Teresa, et al.
Publicado: (2023)

An unusual local invasion of synovial sarcoma
por: Minami, Yusuke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7hlrb78nm9safco87bdcfkfs3b